Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
Anavex Life Sciences (NASDAQ:AVXL), a clinical-stage biopharmaceutical company, will release its fiscal 2025 third quarter financial results on Tuesday, August 12, 2025. The company will host a conference call at 8:30 am ET the same day.
Anavex focuses on developing innovative treatments for various conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other CNS disorders. Management will discuss financial results and provide updates on the company's growth strategy, followed by a Q&A session.
Anavex Life Sciences (NASDAQ:AVXL), un'azienda biofarmaceutica in fase clinica, pubblicher脿 i risultati finanziari del terzo trimestre dell'anno fiscale 2025 il marted矛 12 agosto 2025. La societ脿 terr脿 una conference call lo stesso giorno alle 8:30 ET.
Anavex si concentra sullo sviluppo di trattamenti innovativi per diverse patologie, tra cui morbo di Alzheimer, morbo di Parkinson, schizofrenia, sindrome di Rett e altri disturbi del sistema nervoso centrale. Il management discuter脿 i risultati finanziari e fornir脿 aggiornamenti sulla strategia di crescita dell'azienda, seguiti da una sessione di domande e risposte.
Anavex Life Sciences (NASDAQ:AVXL), una compa帽铆a biofarmac茅utica en etapa cl铆nica, publicar谩 sus resultados financieros del tercer trimestre del a帽o fiscal 2025 el martes 12 de agosto de 2025. La empresa realizar谩 una llamada de conferencia el mismo d铆a a las 8:30 am ET.
Anavex se enfoca en desarrollar tratamientos innovadores para diversas condiciones, incluyendo enfermedad de Alzheimer, enfermedad de Parkinson, esquizofrenia, s铆ndrome de Rett y otros trastornos del sistema nervioso central. La direcci贸n discutir谩 los resultados financieros y proporcionar谩 actualizaciones sobre la estrategia de crecimiento de la compa帽铆a, seguido de una sesi贸n de preguntas y respuestas.
Anavex Life Sciences (NASDAQ:AVXL)電� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 鞝滌暯 須岇偓搿�, 2025 須岅硠鞐半弰 3攵勱赴 鞛 瓴瓣臣毳� 2025雲� 8鞗� 12鞚� 頇旍殧鞚�鞐� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 須岇偓電� 臧欖潃 雮� 霃欕秬 響滌鞁� 鞓れ爠 8鞁� 30攵�鞐� 旎嵓霟办姢 旖滌潉 歆勴枆頃╇媹雼�.
础苍补惫别虫电� 鞎岇笭頃橃澊毹鸽硲, 韺岉偍鞀硲, 鞝曥嫚攵勳棿歃�, 霠堩姼 歃濏泟甑� 氚� 旮绊儉 欷戩稊鞁犼步瓿� 歆堩櫂鞚� 韽暔頃� 雼れ枒頃� 歆堩櫂鞐� 雽�頃� 順侅嫚鞝侅澑 旃橂氩� 臧滊皽鞐� 欤茧牓頃橁碃 鞛堨姷雼堧嫟. 瓴届榿歆勳潃 鞛 瓴瓣臣毳� 雲检潣頃橁碃 須岇偓鞚� 靹膘灔 鞝勲灥鞐� 雽�頃� 斓滌嫚 鞝曤炒毳� 鞝滉车頃� 頉� 歆堨潣鞚戨嫷 鞁滉皠鞚� 臧�歆� 鞓堨爼鞛呺媹雼�.
Anavex Life Sciences (NASDAQ:AVXL), une soci茅t茅 biopharmaceutique en phase clinique, publiera ses r茅sultats financiers du troisi猫me trimestre de l'exercice 2025 le mardi 12 ao没t 2025. La soci茅t茅 tiendra une conf茅rence t茅l茅phonique le m锚me jour 脿 8h30 ET.
Anavex se concentre sur le d茅veloppement de traitements innovants pour diverses pathologies, notamment la maladie d'Alzheimer, la maladie de Parkinson, la schizophr茅nie, le syndrome de Rett et d'autres troubles du syst猫me nerveux central. La direction discutera des r茅sultats financiers et fournira des mises 脿 jour sur la strat茅gie de croissance de l'entreprise, suivies d'une session de questions-r茅ponses.
Anavex Life Sciences (NASDAQ:AVXL), ein biopharmazeutisches Unternehmen in der klinischen Phase, wird die Finanzergebnisse f眉r das dritte Quartal des Gesch盲ftsjahres 2025 am Dienstag, den 12. August 2025 ver枚ffentlichen. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz abhalten.
Anavex konzentriert sich auf die Entwicklung innovativer Behandlungen f眉r verschiedene Erkrankungen, darunter Alzheimer-Krankheit, Parkinson-Krankheit, Schizophrenie, Rett-Syndrom und andere Erkrankungen des zentralen Nervensystems. Das Management wird die Finanzergebnisse besprechen und Updates zur Wachstumsstrategie des Unternehmens geben, gefolgt von einer Fragerunde.
- None.
- None.
Webcast and Conference Call To be Held Tuesday, August 12, 2025, 8:30 am ET
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (鈥淎navex鈥� or the 鈥淐ompany鈥�) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its third fiscal quarter on Tuesday, August 12, 2025.
Management will host a conference call on Tuesday, August 12, at 8:30 am ET to review financial results and provide an update on the execution of the Company鈥檚 growth strategy. Following management鈥檚 remarks, there will be a question-and-answer session.
Webcast / Conference Call Information:
The live of the conference call will be available on Anavex鈥檚 website at .
The conference call can be also accessed by dialing 1 929 205 6099 for participants in the U.S. using the Meeting ID# 856 5033 5285 and reference passcode 014 352. A replay of the conference call will also be available on Anavex鈥檚 website for up to 30 days.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX庐2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX庐2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX庐2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX庐2-73 for the treatment of Parkinson's disease. We believe that ANAVEX庐3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX庐3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at . You can also connect with the Company on , , and .
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company鈥檚 most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email:
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email:
FAQ
When will Anavex Life Sciences (AVXL) report Q3 2025 earnings?
How can investors access Anavex's Q3 2025 earnings call?
What diseases does Anavex Life Sciences focus on treating?
Will there be a replay available of Anavex's Q3 2025 earnings call?
